ABSTRACT
The lymphomas, Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL), are a diverse group of neoplasms that vary widely in age of presentation, patterns of tumor growth, and survival rates. Hodgkin’s disease, or HL was first described by Thomas Hodgkin in 1832, but it is only during the last two decades that the prognosis has improved so that currently HL is curable in the majority of patients. NHL has a variable course, ranging from slow and indolent to aggressive and rapidly fatal. As with HL, improvements in survival rates are largely attributed to advances in therapy. However, the impact of modern imaging methods on the accurate delineation of disease extent and identification of risk factors, both of which facilitate optimized individualized riskadapted treatment with resultant survival benefits, cannot be understimated.
